SCYNEXIS (SCYX) Competitors $1.12 -0.06 (-5.08%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$1.15 +0.03 (+2.68%) As of 09/12/2025 07:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock SCYX vs. GLSI, CLLS, CYBN, CTOR, MOLN, CRDF, ACOG, ZURA, FBRX, and MEIPShould you be buying SCYNEXIS stock or one of its competitors? The main competitors of SCYNEXIS include Greenwich LifeSciences (GLSI), Cellectis (CLLS), Cybin (CYBN), Citius Oncology (CTOR), Molecular Partners (MOLN), Cardiff Oncology (CRDF), Alpha Cognition (ACOG), Zura Bio (ZURA), Forte Biosciences (FBRX), and MEI Pharma (MEIP). These companies are all part of the "pharmaceutical products" industry. SCYNEXIS vs. Its Competitors Greenwich LifeSciences Cellectis Cybin Citius Oncology Molecular Partners Cardiff Oncology Alpha Cognition Zura Bio Forte Biosciences MEI Pharma Greenwich LifeSciences (NASDAQ:GLSI) and SCYNEXIS (NASDAQ:SCYX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, media sentiment, institutional ownership, profitability, earnings, analyst recommendations, valuation and risk. Do insiders and institutionals have more ownership in GLSI or SCYX? 4.2% of Greenwich LifeSciences shares are owned by institutional investors. Comparatively, 54.4% of SCYNEXIS shares are owned by institutional investors. 51.7% of Greenwich LifeSciences shares are owned by insiders. Comparatively, 4.9% of SCYNEXIS shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Is GLSI or SCYX more profitable? Greenwich LifeSciences has a net margin of 0.00% compared to SCYNEXIS's net margin of -599.05%. SCYNEXIS's return on equity of -43.04% beat Greenwich LifeSciences' return on equity.Company Net Margins Return on Equity Return on Assets Greenwich LifeSciencesN/A -700.90% -455.64% SCYNEXIS -599.05%-43.04%-28.21% Do analysts recommend GLSI or SCYX? Greenwich LifeSciences currently has a consensus target price of $42.00, suggesting a potential upside of 274.00%. Given Greenwich LifeSciences' stronger consensus rating and higher possible upside, research analysts clearly believe Greenwich LifeSciences is more favorable than SCYNEXIS.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Greenwich LifeSciences 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00SCYNEXIS 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has more risk and volatility, GLSI or SCYX? Greenwich LifeSciences has a beta of 1.66, indicating that its stock price is 66% more volatile than the S&P 500. Comparatively, SCYNEXIS has a beta of 1.75, indicating that its stock price is 75% more volatile than the S&P 500. Which has higher valuation and earnings, GLSI or SCYX? Greenwich LifeSciences has higher earnings, but lower revenue than SCYNEXIS. Greenwich LifeSciences is trading at a lower price-to-earnings ratio than SCYNEXIS, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGreenwich LifeSciencesN/AN/A-$15.79M-$1.36-8.26SCYNEXIS$3.26M14.42-$21.29M-$0.40-2.80 Does the media refer more to GLSI or SCYX? In the previous week, Greenwich LifeSciences had 8 more articles in the media than SCYNEXIS. MarketBeat recorded 9 mentions for Greenwich LifeSciences and 1 mentions for SCYNEXIS. SCYNEXIS's average media sentiment score of 1.89 beat Greenwich LifeSciences' score of 0.35 indicating that SCYNEXIS is being referred to more favorably in the news media. Company Overall Sentiment Greenwich LifeSciences Neutral SCYNEXIS Very Positive SummarySCYNEXIS beats Greenwich LifeSciences on 8 of the 15 factors compared between the two stocks. Get SCYNEXIS News Delivered to You Automatically Sign up to receive the latest news and ratings for SCYX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SCYX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SCYX vs. The Competition Export to ExcelMetricSCYNEXISMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$46.96M$2.54B$5.78B$10.18BDividend YieldN/A57.24%5.73%4.60%P/E Ratio-2.8023.6475.4626.02Price / Sales14.42545.33464.4091.13Price / CashN/A27.5625.8129.91Price / Book0.775.3812.166.25Net Income-$21.29M$32.95M$3.29B$270.76M7 Day Performance22.12%1.21%0.73%2.54%1 Month Performance33.35%5.08%4.41%5.73%1 Year Performance-23.29%-1.67%62.61%25.85% SCYNEXIS Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SCYXSCYNEXIS1.6202 of 5 stars$1.12-5.1%N/A-23.3%$46.96M$3.26M-2.8060Positive NewsGap UpHigh Trading VolumeGLSIGreenwich LifeSciences1.5367 of 5 stars$11.17+2.2%$42.00+276.0%-24.8%$148.98MN/A-8.213CLLSCellectis3.363 of 5 stars$2.74+2.2%$4.00+46.0%+28.4%$148.96M$49.22M-3.34290Short Interest ↓CYBNCybin2.6777 of 5 stars$6.27-6.8%$85.00+1,255.7%N/A$147.91MN/A-1.4350CTORCitius Oncology1.7909 of 5 stars$1.84-2.1%$3.00+63.0%+17.2%$147.34MN/A0.00N/AMOLNMolecular Partners2.2627 of 5 stars$3.59+0.3%$8.00+122.8%-29.6%$144.54M$5.65M-1.73180CRDFCardiff Oncology3.0237 of 5 stars$2.23+2.8%$10.63+376.5%-24.4%$144.36M$680K-2.5620News CoveragePositive NewsACOGAlpha Cognition2.6991 of 5 stars$9.55+7.3%$20.00+109.4%N/A$143.83MN/A-5.97N/APositive NewsHigh Trading VolumeZURAZura Bio3.8068 of 5 stars$2.21+0.5%$14.00+533.5%-45.9%$143.04MN/A-3.163Short Interest ↓FBRXForte Biosciences3.3525 of 5 stars$11.13-1.2%$68.00+511.0%+45.1%$139.99MN/A-0.685MEIPMEI Pharma1.4811 of 5 stars$3.00-29.1%N/A+5.2%$138.91MN/A-0.63100Upcoming EarningsGap UpHigh Trading Volume Related Companies and Tools Related Companies GLSI Alternatives CLLS Alternatives CYBN Alternatives CTOR Alternatives MOLN Alternatives CRDF Alternatives ACOG Alternatives ZURA Alternatives FBRX Alternatives MEIP Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SCYX) was last updated on 9/15/2025 by MarketBeat.com Staff From Our PartnersOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SCYNEXIS, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share SCYNEXIS With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
